HN user

pcrh

3,161 karma
Posts39
Comments1,273
View on HN
blogs.loc.gov 1mo ago

Accessing Our Digital Past in the Manuscript Division Reading Room, 2022

pcrh
1pts0
www.science.org 2mo ago

The Latest News in Vaccine Obstruction

pcrh
30pts0
www.science.org 10mo ago

RFK Jr. Must Go. and He's Not the Only One

pcrh
20pts5
www.whitehouse.gov 1y ago

Restoring Gold Standard Science

pcrh
1pts1
www.nature.com 1y ago

Over 10% increase in crop yields with a simple spray

pcrh
2pts1
blogs.nature.com 2y ago

Fibonacci's Real Mathematical Legacy

pcrh
1pts0
www.economist.com 2y ago

What Is the Loveliest Language?

pcrh
2pts0
www.nature.com 2y ago

A search for life on Earth from the Galileo spacecraft

pcrh
1pts1
www.nature.com 2y ago

Medical-evidence giant Cochrane battles funding cuts and closures

pcrh
113pts65
www.nature.com 2y ago

Solid-body trajectoids shaped to roll along desired pathways

pcrh
8pts0
www.nature.com 3y ago

Searching the web for science: how small mistakes create big problems

pcrh
1pts0
www.science.org 3y ago

Ask the Oracle (ChatGPT and Chemistry)

pcrh
1pts0
old.reddit.com 3y ago

What's Going on in the Philosophy of Computer and Data Science?

pcrh
1pts0
www.bbc.co.uk 4y ago

Aerospace charts a future without jet fuel

pcrh
1pts1
www.nature.com 4y ago

Nanokelvin-resolution thermometry at room temperature

pcrh
54pts15
drugbaron.com 4y ago

Why Small Beats Big: The Hidden Cost of Too Many Voices

pcrh
2pts0
science.sciencemag.org 5y ago

Beware explanations from AI in health care

pcrh
53pts51
www.gchq.gov.uk 5y ago

The Turing Challenge

pcrh
4pts0
www.bbc.co.uk 9y ago

Rosetta ends its mission

pcrh
296pts61
www.theguardian.com 9y ago

Why Bad Ideas Refuse to Die

pcrh
32pts16
www.smithsonianmag.com 10y ago

How the Green Book Helped African-American Tourists Navigate a Segregated Nation

pcrh
3pts0
youarenotsosmart.com 11y ago

Survivorship Bias

pcrh
4pts0
www.washingtonpost.com 11y ago

Dutch honor Americans’ graves in display of gratitude

pcrh
5pts0
www.bbc.co.uk 11y ago

Drug-delivery pioneer wins £1m engineering prize

pcrh
19pts5
www.nature.com 12y ago

Physics: The Large Human Collider. Anthropology at CERN.

pcrh
1pts0
www.news-journal.com 12y ago

Juveniles facing lifelong terms despite rulings

pcrh
1pts0
thediplomat.com 12y ago

China's Shadow Currency

pcrh
2pts0
medium.com 12y ago

The world’s wind patterns, with temperature, fire, rainfall, and dust

pcrh
1pts0
blogs.nature.com 12y ago

Scientist sacked by British Gov't gets 2013 John Maddox Prize

pcrh
1pts0
www.jsonline.com 12y ago

Learning to dissect a human body.

pcrh
3pts0

I can't imagine that the same factors aren't at play in the scientific research community

I can't speak for the entire scientific research community, but I can say that for basic biomedical research (not clinical research), LLMs are mostly ignored. They simply don't have the ability to parse most raw wet lab data.

This obviously has not stopped the creation of a legion of startups, new Asst Profs, etc, claiming that they are using "AI" to crack new frontiers. In practice, the most effective of these use machine learning, rather than LLMs.

“We can do neuroscience on A.I. systems in a way that we kind of can’t with humans,” Mr. Long said, in that they “don’t have skulls.” The three jobs Eleos was hiring for would all be machine-learning research scientists who could design and perform experiments.

This is pretty interesting! I wouldn't know how easy such "surgery" on LLMs would be to do, if if they do have "knowledge" or "consciousness" as their proponents claim, there could be some profound outcomes from this.

I would have thought that the right to privacy as a fundamental human right would have been sufficient. But apparently not....

Equally, there is abundant precedent for forbidding interference with old-fashioned postal communications, that seemingly doesn't translate to electronic communications...

There's a risk of echos of Theranos here. A paper apparently describing this ultrasound approach has been uploaded to arXiv [0]. If so, the resolution demonstrated is nowhere near sufficient to detect small changes to anatomy, let alone monitor them over time. Future developments could obviously improve on that.

[0] “Whole Cross-Sectional Human Ultrasound Tomography” https://arxiv.org/pdf/2307.00110

You will notice that the criticism this judgement receives if not for finding Song guilty, even if the sentence is inordinately long for a non-lethal crime with minor wider repercussions.

The criticism this judgement receives is the fact that the prosecutors and judge drew these lines of association into a "terrorist organization" so much that even merely possessing literature tangentially related to this non-existent "organization" was deemed a crime worthy of 30 years imprisonment. This is the sort of thinking that sent people to the Soviet Gulags.

I noticed the prominence of celery, which might surprise a modern diner. I had reason some years ago to look into this and the history is interesting. Celery was at one time difficult to cultivate, growing only in select marshlands. In the absence of refrigeration it was also difficult to transport to city diners, so was considered a delicacy.

This also lead to the production of specific table items intended to display celery such as the vase shown in the menus above.

https://slicesofbluesky.com/celery-restaurant-menus/

Would someone be able to comment on this:

Why is it not possible to require websites that wish to market to children to be certified as "child safe". Such sites would be audited by an independent entity that would grant them some form of encrypted key. These could be in age bands, e.g. <6yr, <12 yrs, <16 yrs, etc. also also possibly geographically.

We do this for many other things, from toys to public venues.

Parents could then set their child's device to only allow access to sites with the appropriate certification.

This way the children are as safe as their parents allow them to be, without sharing their child's identity, and the rest of the population also doesn't have to share their identity with dubious authentication service or the government.

There's probably something wrong with this idea, if so I'd be glad to hear it!

Thanks for the article.

I actually read your article some time ago, having found it via SSC. One comment I would make is that the pathology and genetics of AD implicate APP without much doubt. In the field, there isn't much argument against it, even by those who work on tau. Divergences in opinion more often focus on which is the better target for drug therapy.

For example, Derek Lowe's articles on AD do not argue against an APP-tau-neurodegeneration pathway (I am a regular reader of his blog), but argue that targeting amyloid is unlikely to work as a drug therapy. This argument is sometimes extended by Lowe and others to questioning whether Aβ per se is the agent that triggers the downstream effects of either mutating APP or otherwise disrupting its biology. It is possible that Aβ is a by-product of the "true" APP-triggered pathway, see the arguments in favor of C-terminal fragments I linked to earlier.

A fundamental problem the field faces is that it is difficult to experimentally induce actual AD in animals, and so it is difficult to scientifically test hypotheses as to what might cause it. Compare perhaps to something like diabetes. Exactly why mice do not develop realistic AD is unknown.

In addition, there have been literally hundreds of publications (minimum 300) claiming to reverse "Alzheimer's disease" in mice, and the only ones that have lead to any kind of meager success are those using the antibodies. The arguments made in the 2010 review below by Zahs and Ashe [0] remain mostly true sixteen years later.

The recent clinical trials, e.g. Lecanemab, are of interest not only because they might provide at least some benefit, but also because they might represent the first actual scientific experiments showing that removing Aβ can ameliorate the disease, even if only slightly because of the late stage at which they have so far been tested.

Currently ongoing trials using anti-Aβ antibodies and targeting earlier phases of the disease in those with inherited mutations are of keen interest. If these demonstrate clear prevention of disease progression, then the Aβ hypothesis can be considered tested and proven. If not, then the Aβ hypothesis should be abandoned. This would however still not disprove an APP-focused hypothesis.

[0] 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? https://alzped.nia.nih.gov/sites/default/files/2022-09/zahs....

P.S.

As you have demonstrated an interest in this topic, but are not an active researcher, I suggest that you become familiar with Alzforum [www.alzforum.org]. It provides reputable summaries and comments from leading researchers on topical issues and papers in Alzheimer's and related neurodegenerative diseases.

They're still fairly technical, but not as dense as the original papers. Here is an example related to our discussion: https://www.alzforum.org/news/research-news/app-c-terminal-f...

No APP-alone mouse gets neurodegeneration resembling that seen in the human AD brain, i.e. with so-called "neuritic" plaques, tauopathy, spongiopathy and widespread neuronal death.

This is why researchers now most often use the 5XFAD mouse, which has APP with three mutations, and presenilin with two mutations (hence 5 FAD mutations) [0]. Note however that mutated presenilin alone is enough to cause neurodegeneration in mice, such mice however do not accumulate amyloid, which is why mutated APP in added to make the pathology more "realistic".

As to Aβ42, there are mutations in APP which cause familial AD, but produce exclusively Aβ40, e.g. APP A673V [1]. Note also that most studies report alterations in the ratio of Aβ42 to Aβ40, precisely because effects on the levels of Aβ production are inconsistent across APP mutations.

Nevertheless..... and despite my obvious skepticism towards the amyloid toxicity hypothesis, the mutations in APP that cause AD all cluster in or near the region of the protein that is Aβ. There must be a reason for that. It is also in contrast to presenilin, where the mutations are distributed throughout the molecule, indication a loss of presenilin function causes AD.

One alternate explanation to Aβ or oligomer toxicity is proposed toxicity of the immediate precursor to Aβ, i.e. the APP C-terminal fragment (CTF), see for example the recent paper below and references therein [2].

[0] https://www.alzforum.org/research-models/5xfad-b6sjl

[1] A Recessive Mutation in the APP Gene with Dominant-Negative Effect on Amyloidogenesis https://pmc.ncbi.nlm.nih.gov/articles/PMC2728497/

[2] APP β-CTF triggers cell-autonomous synaptic toxicity independent of Aβ https://pmc.ncbi.nlm.nih.gov/articles/PMC12017768/

These points still don't explain how mutations in APP cause AD.

Note that not all AD-causing mutations in APP also cause amyloid accumulation, for example APP-Osaka (loss of APP residue E693) results in familial AD without any accumulation of amyloid [0]. (One can ignore claims that this mutation increases Abeta oligomers, since the evidence is that Abeta oligomers are found at far too low concentrations in the human brain. They would have to be more toxic than ricin if they were etiological for AD). The oligomers seen on gels are an artefact, see the controversy surrounding Tessier-Lavigne).

As you state, and I agree, APP is upstream of tau in natural AD pathogenesis, but does not cause neurodegeneration in mice. So we still don't know from direct experimentation how APP leads to tauopathy and neuodegeneration. The evidence that this is through Abeta per se is tentative at best.

[0] A Second Pedigree with Amyloid-less Familial Alzheimer’s Disease Harboring an Identical Mutation in the Amyloid Precursor Protein Gene (E693delta) https://pubmed.ncbi.nlm.nih.gov/25743013/

Yes, there is a clear sequence of how AD pathology develops, starting with amyloidopathy and progressing to tauopathy, but 1) there is as yet no established molecular connection between the two, and 2) one should not conflate pathology with disease mechanisms.

So, taking the amyloid hypothesis itself (putting presenilin aside for the time being).

We know that mutations in APP do cause AD. How? And if amyloid is not the "proximate" cause of AD, how do mutations in APP cause AD? Include in this Down syndrome, where >90% of cases develop early onset AD by age 50. They have an extra copy of APP that is not mutated.

Furthermore, people can accumulate large amounts of amyloid in the brain without having any notable dementia.

Adding tau to the equation does not help much in explaining how APP mutations cause AD. All people have tau. Furthermore, mutations in tau do not cause AD, they cause different neurodegenerative diseases (e.g. frontotemporal dementia).

Combining APP mutations with presenilin mutation and/or tau mutations in mice does lead to worse outcomes, but the same could be said for combining any other random set of neurodegeneration-associated gene mutations.